LMR Partners’s Accelerate Diagnostics AXDX Stock Holding History

LMR Partners’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,177	Closed	-$18K	–	1116
2022 Q3	$18K	Hold	1,177	–	–	﹤0.01%	1170
2022 Q2	$12K	Buy	+1,177	New	+$10.4K	﹤0.01%	1252

Other funds holding AXDX

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

LMR Partners's AXDX Position: Q4 2022 in Review

LMR Partners sold out of Accelerate Diagnostics (AXDX) in Q4 2022, closing a stake of 1,177 shares — an estimated $18K sold.

LMR Partners first reported a position in AXDX in Q2 2022 and held it in 2 quarters. The position peaked at $18K in Q3 2022. 73 funds tracked by Wall St. Rank hold AXDX as of Q4 2022.

LMR Partners reported no remaining Accelerate Diagnostics position as of Q4 2022 after selling out during the quarter.
LMR Partners sold 1,177 Accelerate Diagnostics shares in Q4 2022, an estimated $18K.
LMR Partners first reported a position in Accelerate Diagnostics in Q2 2022 and held it in 2 quarters.
LMR Partners's Accelerate Diagnostics position peaked at $18K in Q3 2022.
73 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2022.

Based on LMR Partners's 13F filing for Q4 2022, filed 14 Feb 2023.